The CEA Registry Blog

Dec 16

by CEA Registry Team 12/16/2011 7:35 PM  RssIcon

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Kim S, Mortaz Hedjri S, Coyte PC, et al. Cost-utility of lumbar decompression with or without fusion for patients with symptomatic degenerative lumbar spondylolisthesis. Spine J. 2011 Dec 9. [Epub ahead of print] PubMed PMID: 22169001.

2: Soini E, Hallinen T, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2011 Dec 14. [Epub ahead of  print] PubMed PMID: 22168785.

3: Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T, Tsuruya K, Yoshida H, Iseki K, Watanabe T. Cost-effectiveness of chronic kidney disease mass screening test in Japan.  Clin Exp Nephrol. 2011 Dec 14. [Epub ahead of print] PubMed PMID: 22167460.

4: Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One. 2011;6(12):e26783.  Epub 2011 Dec 2. PubMed PMID: 22164204; PubMed Central PMCID: PMC3229483.

5: Nosyk B, Sharif B, Sun H, Cooper C, Anis AH; on behalf of the CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human  mmunodeficiency Virus. PLoS One. 2011;6(12):e27059. Epub PMID: 22162988

6: Palmer AJ, Tucker DM. Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis. Prim Care Diabetes. 2011 Dec 6. [Epub ahead of print] PubMed PMID: 22153888.

7: Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value  Health. 2011 Dec;14(8):1068-77. PubMed PMID: 22152176.

8: Hoyle M, Rogers G, Moxham T, Liu Z, Stein K. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011 Dec;14(8):1057-67. PMID: 22152175.

9: Simpson KN, Baran RW, Kirbach SE, et al. Economics of Switching to Second-Line Antiretroviral Therapy with Lopinavir/Ritonavir in Africa: Estimates  Based on DART Trial Results and Costs for Uganda and Kenya. Value Health. 2011 Dec;14(8):1048-54. PMID: 22152173.

10: Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011 Dec;14(8):1039-47. PMID: 22152172.

11: Fang C, Otero HJ, Greenberg D, et al. Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health. 2011 Dec;14(8):1010-8. PMID: 22152169.

12: Park H, Rascati KL, Keith MS, et al. Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. Value Health. 2011 Dec;14(8):1002-9. PMID: 22152168.

13: Thongprasert S, Permsuwan U, Ruengorn C, et al.  Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer. Asia Pac J Clin Oncol. 2011 Dec;7(4):369-75. PMID: 22151987.

14: Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. 2011 Dec 6;155(11):751-61. PMID: 22147714.

15: Galper BZ, Moran A, Coxson PG, et al. Using Stress Testing to Guide Primary Prevention of Coronary Heart Disease among Intermediate-Risk Patients: A Cost-effectiveness Analysis. Circulation. 2011 Dec 5. [Epub ahead of print] PMID: 22144567.

16: Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011 Dec;15(40):1-210. PMID: 22142554.

17: Lee K, Chow P, Wu D, et al. An Economic Analysis between Entecavir and  Lamivudine for the Treatment of Chronic Hepatitis B in Hong Kong. J Gastroenterol Hepatol. 2011 Dec 6. [Epub ahead of print] PMID: 22141402.

18: Hall PS, McCabe C, Stein RC, Cameron D. Economic Evaluation of Genomic Test-Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer. J Natl Cancer Inst. 2011 Dec 2. [Epub ahead of print] PMID: 22138097.

19: Postmus D, Abdul Pari AA, Jaarsma T, et al. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am Heart J. 2011 Dec;162(6):1096-104. PMID: 22137084.

20: Wang TS, Cheung K, Farrokhyar F, et al. Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism. Surgery. 2011 Dec;150(6):1286-94. PMID: 22136852.

21: McKenna C, Maund E, Sarowar M, et al. Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Dec 2. [Epub ahead of print] PMID: 22136303.

22: McGarry LJ, Pawar VS, Parekh HH, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2011 Dec 2. [Epub ahead of print] PMID: 22135116.

23: Calvo Aller E, Maroto P, Kreif N, et al. Cost-effectiveness evaluation of sunitinib  as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Transl Oncol. 2011 Dec;13(12):869-77. PMID: 22126730.

24: Shauver MJ, Clapham PJ, Chung KC. An economic analysis of outcomes and complications of treating distal radius fractures in the elderly. J Hand Surg Am. 2011 Dec;36(12):1912-1918.e3. PMID: 22123045.

25: Joshi JK, Ouyang B, Prabhakaran S. Should TIA patients be hospitalized or referred to a same-day clinic?: A decision analysis. Neurology. 2011 Dec 13;77(24):2082-8. PMID: 22094477.

26: Baker TM, Goh Jo W, Johnston A, Falvey H, et al. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. J Med Econ. 2011 Dec 5. [Epub ahead of print] PMID: 22084957.

27: Carlos F, Ramírez-Gámez J, Dueñas H, et al. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico. J Med Econ. 2011 Dec 5. [Epub ahead of print] PMID: 22082033.

28: Dakin H, Sherman M, Fung S, Fidler C, Bentley A. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a canadian public payer perspective. Pharmacoeconomics. 2011 Dec 1;29(12):1075-91. PMID: 22077579.

29: Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, et al. Pharmacoeconomic assessment of implementing  a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine. 2011 Dec 6;29(52):9640-8. PMID:22027484.

30: Lock K, Wilson K, Murphy D, et al. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2011 Dec;12(17):2613-26 PMID: 22017336.

31: Cahill AG, Odibo AO, Stout MJ, et al. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis. Am J Obstet Gynecol. 2011 Dec;205(6):542.e1-7. PMID: 22000669.

32: Straub N, Grunert P, von Kries R, et al. Health economic potential of early nutrition programming: a model calculation of long-term reduction in blood  pressure and related morbidity costs by use of long-chain polyunsaturated fatty acid-supplemented formula. Am J Clin Nutr. 2011 Dec;94(6):2030S-5S. PMID: 21974892.

33: Dickson R, Bagust A, Boland A, et al. Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Dec 1;29(12):1051-62. PMID: 21967156.

34: Ekers D, Godfrey C, Gilbody S, et al. Cost utility of behavioural activation delivered by the non-specialist. Br J Psychiatry. 2011 Dec;199:510-1.  PMID: 21947655.

35: Fritzell P, Ohlin A, Borgström F. Cost-Effectiveness of Balloon Kyphoplasty Versus Standard Medical Treatment in Patients With Osteoporotic Vertebral Compression Fracture: A Swedish Multicenter Randomized Controlled Trial With 2-Year Follow-up. Spine (Phila Pa 1976). 2011 Dec 15;36(26):2243-51. PMID: 21912321.

36: Sud S, Mittmann N, Cook DJ, et al. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation. Am J Respir Crit Care Med. 2011 Dec 1;184(11):1289-98.  PMID: 21868500.

37: Tran-Duy A, Boonen A, van de Laar MA, et al. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis. 2011 Dec;70(12):2111-8.  PMID: 21857027.

38: Kowada A. Cost-effectiveness of interferon-γ release assay versus chest X-ray for tuberculosis screening of employees. Am J Infect Control. 2011 Dec;39(10):e67-72.  PMID: 21839543.

39: Tsuchiya T, Fukuda T, Furuiye M, et al. Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. Lung Cancer. 2011 Dec;74(3):521-8. PMID: 21570734.

40: Botteman MF, Meijboom M, Foley I, et al. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur J Health Econ. 2011 Dec;12(6):575-88. PMID: 20809091.

By James D. Chambers

 


Your name:
Title:
Comment:
Security Code
CAPTCHA image
Enter the code shown above in the box below
Add Comment   Cancel 

Please view the blog archive for earlier entries

Search This Blog